Core Viewpoint - The company, Shanxi Dayu Biological Engineering Co., Ltd., reported a significant increase in revenue for the year 2025, but continued to face net losses, marking the third consecutive year of losses since 2023 [1][2]. Group 1: Financial Performance - The company achieved an operating income of 168 million yuan, representing a year-on-year growth of 36.78% [1]. - The net profit attributable to shareholders was a loss of 28.79 million yuan, which is a 20.23% increase in the loss compared to the previous year [1]. - Total assets are expected to reach 434 million yuan by the end of 2025, reflecting a growth of 10.39% from the beginning of the year [2]. - The equity attributable to shareholders decreased by 9.81% to 265 million yuan, with the net asset per share dropping to 2.39 yuan [2]. - The weighted average return on equity fell to -10.32%, further declining compared to the previous year [2]. Group 2: Business Segments - The revenue growth in 2025 was primarily driven by the newly expanded pig farming business, which contributed 42.19 million yuan to the total revenue [1]. - The pig farming segment's profitability was adversely affected by a significant drop in market prices in the fourth quarter of 2025, leading to increased net losses by 4.84 million yuan compared to the previous year [1]. - Traditional business segments, including feed additives, feed, and veterinary drugs, faced challenges due to industry capacity adjustments and the impact of African swine fever, resulting in a decline in gross profit [1].

Core Viewpoint - Dayu Biological announced an expected net profit attributable to shareholders for 2025 to be between -300 million to -260 million yuan, indicating a decline compared to the previous year's loss of -239.43 million yuan, with a change rate of -25.30% to -8.59% [2] Financial Performance - The projected net profit for 2025 is estimated to be in the range of -300 million to -260 million yuan [2] - The previous year's net profit was -239.43 million yuan, showing a significant expected increase in losses for the upcoming year [2] - The percentage change in net profit is forecasted to be between -25.30% and -8.59% compared to the previous year [2]

Core Viewpoint - Dayu Biological announced the approval of several proposals at its first extraordinary shareholders' meeting in 2026, including the conclusion of certain fundraising projects and the allocation of surplus funds to supplement working capital [2] Group 1: Proposals Approved - The company approved the proposal to conclude certain fundraising projects and permanently allocate surplus funds to working capital [2] - The company also approved a proposal regarding expected routine related-party transactions for 2026 [2] - Additionally, the company approved a proposal to apply for comprehensive credit facilities from banks, other financial institutions, and leasing companies in 2026 [2]

Core Viewpoint - Dayu Biological announced the approval of several proposals, including the completion of certain fundraising projects and the permanent allocation of surplus funds to supplement working capital [2] Group 1 - Dayu Biological's fourth board meeting approved the proposal regarding the completion of certain fundraising projects [2] - The company will permanently allocate surplus fundraising funds to enhance its working capital [2]

Core Insights - The animal health sector experienced a slight increase of 0.42% on December 19, with Huisheng Biological leading the gains [1] - The Shanghai Composite Index closed at 3890.45, up 0.36%, while the Shenzhen Component Index closed at 13140.22, up 0.66% [1] Stock Performance - Huisheng Biological (300871) closed at 20.75, with a rise of 2.47% and a trading volume of 45,200 shares, amounting to a transaction value of 92.96 million yuan [1] - Other notable performers included: - Qudongli (920275) at 9.27, up 2.43% [1] - Shenlian Biological (688098) at 9.01, up 2.15% [1] - Xianfeng Holdings (002141) at 3.74, up 1.91% [1] - Ruipu Biological (300119) at 19.60, up 1.87% [1] Capital Flow - The animal health sector saw a net outflow of 129 million yuan from institutional investors, while retail investors contributed a net inflow of 157 million yuan [2][3] - The detailed capital flow for selected stocks showed: - Xianfeng Holdings (002141) had a net inflow of 6.89 million yuan from institutional investors [3] - Ruipu Biological (300119) experienced a net outflow of 15.98 million yuan from institutional investors but a net inflow of 11.27 million yuan from retail investors [3] - Qudongli (920275) had a net inflow of 2.22 million yuan from retail investors [3]

Group 1 - The pork sector opened high, with Dayu Bio and Aonong Bio rising over 9% [1] - Dongrui Co., Delisi, and Zhenghong Technology also experienced gains [1]

Core Insights - The animal health sector experienced a decline of 0.24% on November 17, with Dayu Biological leading the drop [1] - The Shanghai Composite Index closed at 3972.03, down 0.46%, while the Shenzhen Component Index closed at 13202.0, down 0.11% [1] Stock Performance - Notable gainers included: - Qudongli (code: 920275) with a closing price of 10.68, up 5.12% [1] - *ST Lvkang (code: 002868) with a closing price of 42.57, up 5.01% [1] - Houfeng Holdings (code: 002141) with a closing price of 3.91, up 2.62% [1] - Major decliners included: - Dayu Biological (code: 920970) with a closing price of 8.70, down 3.87% [2] - Ruipu Biological (code: 300119) with a closing price of 20.61, down 2.92% [2] - Zhongmu Co., Ltd. (code: 600195) with a closing price of 7.94, down 1.98% [2] Capital Flow - The animal health sector saw a net outflow of 10.15 million yuan from institutional investors, while retail investors experienced a net outflow of 20.76 million yuan [2] - Conversely, speculative funds recorded a net inflow of 30.91 million yuan [2] Individual Stock Capital Flow - Notable capital flows included: - Biological Shares (code: 600201) with a net inflow of 12.08 million yuan from institutional investors [3] - Xianfeng Holdings (code: 002141) with a net inflow of 9.50 million yuan from institutional investors [3] - Ruipu Biological (code: 300119) with a net inflow of 1.05 million yuan from speculative funds [3] - Decliners in capital flow included: - *ST Lvkang (code: 002868) with a net outflow of 0.79 million yuan from institutional investors [3] - Hai Li Biological (code: 603718) with a net outflow of 2.82 million yuan from institutional investors [3]

Summary of Stock Buyback Activities on October 30 Core Insights - On October 30, a total of 26 companies announced 27 stock buyback-related updates, indicating a significant activity in the market [1] Group 1: New Buyback Proposals - 16 companies disclosed stock buyback proposals for the first time, with 6 companies proposing buyback amounts exceeding 10 million [1] - The highest proposed buyback amounts were from HeMai Co., Ltd. (up to 200 million), Sanli Shi (60 million), and Minsheng Health (50.544 million) [1] Group 2: Approved Buyback Plans - 2 companies had their buyback plans approved by shareholders, with the highest proposed amounts from Dayu Biological (up to 5.596 million) and New Weiling (20,200) [1] Group 3: Buyback Implementation Progress - 2 companies reported on the implementation of their buyback plans, with the highest amounts from Guyue Longshan (186 million) and Jiayi Co. (99.0246 million) [1] Group 4: Completed Buybacks - 5 companies completed buybacks exceeding 10 million, with the highest completed amounts from Huafa Co. (310 million), Shenzhou Digital (203 million), and Ruoyu Chen (200 million) [1] - As of October 30, a total of 1711 buyback plans have been completed this year, involving 1281 companies, with 330 companies completing buybacks exceeding 100 million [1] - The leading companies in completed buyback amounts include Kweichow Moutai (6 billion), Muyuan Foods (3 billion), and COSCO Shipping Holdings (2.146 billion) [1]

Core Viewpoint - The animal health sector experienced a decline of 0.36% on October 22, with Dayu Biological leading the drop. The Shanghai Composite Index closed at 3913.76, down 0.07%, while the Shenzhen Component Index closed at 12996.61, down 0.62% [1]. Stock Performance Summary - The following stocks in the animal health sector showed varied performance: - Shengwu Co. (600201) closed at 10.78, up 0.56% with a trading volume of 327,000 shares and a turnover of 351 million yuan - Ruipu Biological (300119) closed at 21.50, up 0.51% with a trading volume of 73,200 shares and a turnover of 158 million yuan - Haili Biological (603718) closed at 7.04, up 0.28% with a trading volume of 44,200 shares and a turnover of 31.17 million yuan - Dayu Biological (920970) closed at 9.46, down 1.25% with a trading volume of 20,800 shares and a turnover of 19.89 million yuan - ST Lvkang (002868) closed at 28.49, down 1.18% with a trading volume of 9,904 shares and a turnover of 28.26 million yuan [1][2]. Capital Flow Analysis - The animal health sector saw a net outflow of 47.45 million yuan from institutional investors, while retail investors contributed a net inflow of 36.66 million yuan. Speculative funds recorded a net inflow of 10.80 million yuan [2][3]. - Specific stock capital flows included: - Shunlian Biological (688098) had a net inflow of 6.94 million yuan from institutional investors but a net outflow of 12.58 million yuan from retail investors - Ruipu Biological (300119) experienced a net outflow of 2.94 million yuan from institutional investors, with a significant net inflow of 13.74 million yuan from speculative funds [3].

Core Viewpoint - Dayu Biological is increasing its investment in pig farming despite ongoing pressure in the pig breeding industry, aiming to extend its industrial chain and stabilize its feed sales channels [2][4]. Company Summary - Dayu Biological's wholly-owned subsidiary, Shanxi Dayu Animal Husbandry Co., Ltd., plans to invest 50 million yuan in its other subsidiary, Puxian Dayu Smart Animal Husbandry Industry Development Co., Ltd., raising its registered capital from 30 million yuan to 80 million yuan [2]. - The company primarily focuses on the research, production, and sales of feed additives, feed, and veterinary drugs, and has faced performance fluctuations since its listing on the Beijing Stock Exchange in 2022, recording its first loss in 2023 [2]. - Financial data shows Dayu Biological's revenue for 2022, 2023, and 2024 was 157 million yuan, 161 million yuan, and 123 million yuan respectively, with net profits of 18.15 million yuan, -2.09 million yuan, and -23.94 million yuan [2]. Industry Summary - The pig farming industry is undergoing structural changes, with a trend towards large-scale operations replacing smallholder farms, impacting Dayu Biological's sales of feed and additives [3]. - The company is adopting a "company + farmer" model to address challenges from the changing structure of downstream farming, having established a fully-owned subsidiary for pig farming in 2024 with an investment of 100 million yuan [3]. - As of August 2025, the national breeding sow inventory reached 40.38 million heads, indicating high production capacity, while pig prices remain low, affecting the profitability of many listed pig companies [4].